WaveMan
WaveMan · Company
OM · Outset Medical, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

OM Outset Medical (OM) Insider Trading, Ownership & Congress Trades

Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001484612
Quote by TradingView
Form 144 · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
49
13F, latest reported quarter

What the filings say about OM

Insiders, 180 days
+$708.0K net bought
1 buyer · 4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$46.6K
3 notices

Outset Medical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Outset Medical, Inc. insiders bought a net $708.0K of stock across 299 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Leonard Braden Michael
BUY
2026-10-05 SECtraded 2026-10-02
16,575
$64.2K
-1.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 1, 2026.
  • The trade is 0.6% of the 2,764,610 shares held after it.
  • No other insider bought within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Leonard Braden Michael bought about $64.2K of OM on Oct 2, 2026; 49 funds added in the latest 13F quarter.
Leonard Braden Michael
BUY
2026-10-05 SECtraded 2026-10-01
228,334
$806.0K
-1.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 8.3% of the 2,748,035 shares held after it.
  • No other insider bought within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Leonard Braden Michael bought about $806.0K of OM on Oct 1, 2026, the largest insider purchase at the company on our record; 49 funds added in the latest 13F quarter.
Gaeta Renee
Chief Financial Officer
SELL
2026-08-18 SECtraded 2026-08-17
4,543
$19.9K
-4.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 3, 2026.
  • The trade is 2.5% of the 180,840 shares held after it.
  • 2 other insiders sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Gaeta Renee sold about $19.9K of OM on Aug 17, 2026; 2 other insiders sold within 30 days and 49 funds added in the latest 13F quarter.
Brottem John L.
General Counsel
SELL
2026-08-18 SECtraded 2026-08-17
2,632
$11.6K
-4.7%
Context
  • 64 earlier Form 4 trades (code P or S) here by this insider (64 sales), the last on May 15, 2026.
  • The trade is 3.0% of the 87,475 shares held after it.
  • 2 other insiders sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Brottem John L. sold about $11.6K of OM on Aug 17, 2026; 2 other insiders sold within 30 days and 49 funds added in the latest 13F quarter.
Trigg Leslie
Chair and CEO
SELL
2026-08-18 SECtraded 2026-08-17
3,437
$15.1K
-4.7%
Context
  • 69 earlier Form 4 trades (code P or S) here by this insider (69 sales), the last on May 15, 2026.
  • The trade is 1.8% of the 194,597 shares held after it.
  • 2 other insiders sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chair and CEO Trigg Leslie sold about $15.1K of OM on Aug 17, 2026; 2 other insiders sold within 30 days and 49 funds added in the latest 13F quarter.
299 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 294 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$708.0K over 180 days
+$823.7K over 90 days · +$870.3K of it by a 10%+ holder
more than 90% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
49 funds bought in last quarter
below 58% of Medical Devices
Revenue
+5.1% year over year
below 66% of Medical Devices
Margin
-68.3% net margin
below 74% of Medical Devices
Buybacks
no share repurchases reported
Short interest
5.5% of the float short (float per yahoo 2026-10-26) · 5.9 days to cover · settled 2026-09-30
more than 58% of Medical Devices
What changed in the last 30 days
Oct 5Insider Leonard Braden Michael bought $870.3K (2 trades, Oct 1 to Oct 2)

Watch OM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-72.8%12M
-80%-53%-26%+1%2025-102025-122026-022026-042026-062026-082026-10 2026-10-01 · Leonard Braden Michael bought $806.0K2026-06-03 · Gaeta Renee sold $87.3K2026-10-02 · Leonard Braden Michael bought $64.2K2026-01-20 · Trigg Leslie sold $60.4K2026-01-20 · Brottem John L. sold $47.7K2026-01-20 · Nash Marc sold $27.5K2026-08-17 · Gaeta Renee sold $19.9K2026-08-17 · Trigg Leslie sold $15.1K2026-05-15 · Trigg Leslie sold $12.7K2026-08-17 · Brottem John L. sold $11.6K2026-02-17 · Trigg Leslie sold $11.3K2026-01-21 · Trigg Leslie sold $10.7K2026-05-15 · Brottem John L. sold $9.8K2026-02-17 · Brottem John L. sold $9.5K2026-01-07 · Trigg Leslie sold $7.7K2025-12-01 · Drexler Karen sold $6.8K2026-02-17 · Nash Marc sold $6.1K2026-01-21 · Brottem John L. sold $5.9K2026-05-15 · Nash Marc sold $5.9K2026-01-21 · Nash Marc sold $4.9K2025-11-17 · Trigg Leslie sold $4.2K2025-11-17 · Brottem John L. sold $1.8K2025-11-17 · Nash Marc sold $1.1K2026-01-07 · Brottem John L. sold $9562026-01-07 · Nash Marc sold $4612026-08-14 · Brottem John L. filed to sell $11.5K2026-08-14 · Gaeta Renee filed to sell $19.9K2026-08-14 · Trigg Leslie filed to sell $15.1K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns OM: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
2,742,887 sh
$11.8M
BML Capital Management, LLC
2,519,701 sh
$10.9M
AQR CAPITAL MANAGEMENT LLC
998,961 sh
$4.3M
PERCEPTIVE ADVISORS LLC
833,333 sh
$3.6M
VANGUARD CAPITAL MANAGEMENT LLC
780,134 sh
$3.4M

Congress trades in OM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

OM planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Brottem John L.
Filed 2026-08-14
$11.5K
Gaeta Renee
Filed 2026-08-14
$19.9K
Trigg Leslie
Filed 2026-08-14
$15.1K

OM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Disruptive Medicine ETF
$166.3K position · as of 2026-05-31
0.4%
Select Health Care Portfolio
$7.4M position · as of 2026-05-31
0.1%
Fidelity Advisor Health Care Fund
$3.7M position · as of 2026-07-31
0.1%
VIP Health Care Portfolio
$1.2M position · as of 2026-06-30
0.1%
Ultra-Small Company Market Fund
$108.0K position · as of 2026-06-30
0.1%
AQR Small Cap Multi-Style Fund
$137.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$4.0M
$2.0M
$1.7M
-98%
-21%
2023
$6.5M
-$742.7K
$2.1M
-90%
-25%
2022
$4.1M
-$1.5M
$1.9M
-55%
-21%
2021
$7.1M
$802.4K
$1.8M
-19%
+4%
2020
$2.8M
$46.4M
$2.9M
-6%
+19%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $708.0K bought by insiders over 180 days, 49 funds added last quarter, $46.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXIRMDLUNG

OM financials

Revenue growth
+5.1%
XBRL, annual
Net margin
-68.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$117.8M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-63.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$38.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.06x
long-term 2026-06-30 plus current 2022-12-31 (42 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.37x
TTM operating cash flow over long-term 2026-06-30 plus current 2022-12-31 (42 months older than the period end)
Return on equity
-59.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-28.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-29.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$144.5M
market value at close 2026-10-23 on 2026-08-04 shares, plus long-term 2026-06-30 plus current 2022-12-31 (42 months older than the period end), minus cash 2026-06-30
FCF yield
-50.4%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$119.5M$113.7M$130.4M$115.4M
Gross profit$46.8M$38.6M$29.0M$17.8M
Operating income-$66.7M-$113.4M-$169.8M-$161.0M
Net income-$81.7M-$128.0M-$172.8M-$163.0M
EPS (diluted)-5.37-36.96-52.28-3.38
Operating cash flow-$46.3M-$116.3M-$131.4M-$145.7M
Cash$35.0M$124.0M$68.5M$73.2M
Long-term debt$96.2M$197.4M$130.1M$96.3M
SEC XBRL, fiscal years, as known on 2026-10-27

OM Stock Sonar score 6/7 axes

Find similar shapesCompare

OM ranks highest on insider conviction (71st percentile) and growth (49th), and lowest on financial health (31st), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
39
Inputs
  • Return on equity-59.2% · 35 pct, sector of 183
  • Return on assets-28.0% · 41 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-29.3% · 40 pct, sector of 188
Financial health
31
Inputs
  • Debt to equity1.06x · 18 pct, sector of 159
  • Cash flow to debt-0.37x · 44 pct, sector of 150
Growth
49
Inputs
  • Revenue growth, YoY+5.1% · 34 pct, sector of 219
  • Backlog growth, YoY+10.6% · 64 pct, sector of 37
Insider conviction
71
Inputs
  • Net Form 4 buying (codes P and S), 180d$708K · 90 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
42
Inputs
  • Funds adding, latest quarter49 · 42 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
41
Inputs
  • Short interest, % of float+5.5% · 45 pct, sector of 240
  • Recalls per $1B revenue, 3y25.11 per $1B · 9 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+7.5% · 69 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

OM filings, in plain words

Are Outset Medical insiders buying or selling OM?

In the 180 days to 2026-10-27, Outset Medical insiders were net buyers, a net $708.0K: $870.3K of purchases and $162.2K of sales reported on Form 4, by 1 buyer and 4 sellers.

Are there planned insider sales of OM?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $46.6K of stock; the latest, by Brottem John L., was filed 2026-08-14.

Read the full summary

In the 180 days to 2026-10-27, Outset Medical insiders were net buyers of OM, a net $708.0K across purchases and sales reported on Form 4 by 1 buyer and 4 sellers. Most of that figure, $870.3K, came from a holder of 10% or more rather than an officer or director. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $46.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies